MG
LABD icon

Marex Group’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Marex Group’s Portfolio LABD Stock Details LABD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,440
Closed -$255K – 292
2022
Q4 		$255K Buy
+1,440
New +$295K 0.04% 209

Other funds holding LABD

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JF
Jump Financial Chicago, Illinois $7.5B AUM 33.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Marex Group's LABD Position: Q1 2023 in Review

Marex Group sold out of Direxion Daily S&P Biotech Bear 3X ETF (LABD) in Q1 2023, closing a stake of 1,440 shares — an estimated $255K sold.

Marex Group first reported a position in LABD in Q4 2022 and held it in 1 quarter. The position peaked at $255K in Q4 2022. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2023.

  • Marex Group reported no remaining Direxion Daily S&P Biotech Bear 3X ETF position as of Q1 2023 after selling out during the quarter.
  • Marex Group sold 1,440 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2023, an estimated $255K.
  • Marex Group first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2022 and held it in 1 quarter.
  • Marex Group's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $255K in Q4 2022.
  • 17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2023.

Based on Marex Group's 13F filing for Q1 2023, filed 2 Apr 2026.